LENZ
Next earnings: Jul 29, 2026
ANALYST COVERAGE5 analysts
BUY
+63.5%upside to target
Buy
480%
Hold
120%
4 Buy (80%)1 Hold (20%)0 Sell (0%)
Full report →
Signal
Leaning Bullish1
Price
1
Move+0.69%Quiet session
Volume
1
Volume1.0× avgNormal activity
Technical
1
RSIRSI 20Oversold — bounce setup
PRICE
Prev Close
7.29
Open
7.18
Day Range6.86 – 7.41
6.86
7.41
52W Range6.83 – 50.40
6.83
50.40
1% of range
VOLUME & SIZE
Avg Volume
949.1K
FUNDAMENTALS
P/E Ratio
-2.0x
Not profitable
EPS (TTM)
Div Yield
No dividend
Key MetricsTTM
Market Cap$230.14M
Revenue TTM$20.99M
Net Income TTM-$109.00M
Free Cash Flow-$87.44M
Gross Margin91.2%
Net Margin-519.3%
Operating Margin-563.8%
Return on Equity-46.8%
Return on Assets-40.0%
Debt / Equity0.00
Current Ratio10.40
EPS TTM$-3.48
Upcoming Events
EEarnings Report
Tomorrow
May 18
DEx-Dividend
In 89 days
Aug 14
PDividend Pay
In 102 days
Aug 27

LENZ News

About

graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process of homology directed repair (hdr) and targeted dna integration to precisely repair genetic defects at their source. graphite bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients’ lives

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
James W. McCollumCo-Founder & Director
Marc G. OdrichChief Medical Officer
Shawn OlssonChief Commercial Officer
Kris GambelinSenior Vice President of Regulatory & Clincal Operations
Daniel R. ChevallardChief Financial Officer
David ChoromanskiVice President of Marketing
Domenick PorfidiaVice President of Sales
Evert SchimmelpenninkPresident, Chief Executive Officer, Secretary & Director
Melissa RosnessSenior Vice President of Manufacturing Operations